UniQure NV (QURE) experienced a significant market surge on Wednesday, July 12, 2023, following a reversal from the FDA regarding its AMT-130 therapy for Huntington’s Disease. The stock opened at approximately $43, peaked at $48.88, and closed in the high $47 range, marking an astounding 81% overnight gain from the previous close of $26.99.
The surge was driven by the FDA’s decision to accept the company’s data for accelerated approval, reversing previous indications that further studies were necessary. This dramatic turnaround reflects a shift from regulatory uncertainty to newfound investor confidence, making QURE one of the year’s top-performing biotech stocks.
QURE’s significant increase was preceded by unusual options buying activity, indicating that institutional investors were positioning themselves early on, as evidenced by substantial options orders ahead of the FDA announcement. As of now, investors are advised to monitor other biotech companies with upcoming catalysts that may offer similar market movements.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
